Chris Wilfong

Chris Wilfong is an experienced professional in the biopharmaceutical industry, currently serving as an Operating Partner at Two River since October 2016, where responsibilities include evaluating investment opportunities and advising senior management teams on business and regulatory strategy. In addition to this role, Chris Wilfong is a Strategic Advisor at both Kronos Bio, Inc. and IconOVir Bio, and held positions as Chief Executive Officer at TRC 2004, Inc. until its acquisition in August 2024, and at 76Bio, Inc. until January 2024. Previously, Chris Wilfong served as Chief Business Officer at Neogene Therapeutics and as a Member of the Board of Directors at Veritas Genetics. Early career roles included Chief Financial Officer positions at Veterinary Prime, Inc. and GenomiCare Biotechnology, as well as Director at Trustbridge Partners, leading the US investment team. Chris Wilfong holds an MBA from MIT Sloan School of Management and a BS in Economics from The Wharton School.